{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Colon+Carcinoma",
    "query": {
      "condition": "Advanced Colon Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 557,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Colon+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T12:10:14.769Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04779554",
      "title": "Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peritoneal Carcinomatosis"
      ],
      "interventions": [
        {
          "name": "Mitomycin C, flat dose 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin C, weight-based dose 12.5 mg/m2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prakash Pandalai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-06-04",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 2,
      "location_summary": "Lexington, Kentucky • Burlington, Vermont",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04779554"
    },
    {
      "nct_id": "NCT03317119",
      "title": "Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colon Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Rectal Carcinoma",
        "RAS Family Gene Mutation",
        "Stage III Colon Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Rectal Cancer AJCC v7",
        "Stage IIIA Colon Cancer AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIA Rectal Cancer AJCC v7",
        "Stage IIIB Colon Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIB Rectal Cancer AJCC v7",
        "Stage IIIC Colon Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IIIC Rectal Cancer AJCC v7",
        "Stage IV Colon Cancer AJCC v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Rectal Cancer AJCC v7",
        "Stage IVA Colon Cancer AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVA Rectal Cancer AJCC v7",
        "Stage IVB Colon Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Stage IVB Rectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine and Tipiracil Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-04-11",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 8,
      "location_summary": "Corona, California • Duarte, California • Lancaster, California + 5 more",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03317119"
    },
    {
      "nct_id": "NCT03290937",
      "title": "Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pharmacodynamic Study",
          "type": "OTHER"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-12-27",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03290937"
    },
    {
      "nct_id": "NCT04354246",
      "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Ovarian Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Plasma Cell Neoplasm",
        "Multiple Myeloma",
        "HNSCC",
        "Microsatellite Stable Colorectal Carcinoma",
        "MSS-CRC"
      ],
      "interventions": [
        {
          "name": "Dose escalation: COM902 monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort expansion: COM902 (RDFE) monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2020-03-31",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 9,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354246"
    },
    {
      "nct_id": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "ERBB2 Gene Amplification",
        "Rectal Adenocarcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Stage III Colon Cancer AJCC v7",
        "Stage III Rectal Cancer AJCC v7",
        "Stage IIIA Colon Cancer AJCC v7",
        "Stage IIIA Rectal Cancer AJCC v7",
        "Stage IIIB Colon Cancer AJCC v7",
        "Stage IIIB Rectal Cancer AJCC v7",
        "Stage IIIC Colon Cancer AJCC v7",
        "Stage IIIC Rectal Cancer AJCC v7",
        "Stage IV Colon Cancer AJCC v7",
        "Stage IV Rectal Cancer AJCC v7",
        "Stage IVA Colon Cancer AJCC v7",
        "Stage IVA Rectal Cancer AJCC v7",
        "Stage IVB Colon Cancer AJCC v7",
        "Stage IVB Rectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HER-2 testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2017-11-27",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 786,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03365882"
    },
    {
      "nct_id": "NCT01495663",
      "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "I-131-CLR1404",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495663"
    },
    {
      "nct_id": "NCT06131398",
      "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 355",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 77,
      "start_date": "2024-03-07",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Merriam",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131398"
    },
    {
      "nct_id": "NCT02729298",
      "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "EGFR Positive Non-small Cell Lung Cancer",
        "Colorectal Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "BRAF-Mutated Melanoma"
      ],
      "interventions": [
        {
          "name": "TP-0903",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2016-12-14",
      "completion_date": "2022-06-29",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02729298"
    },
    {
      "nct_id": "NCT03058289",
      "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma",
        "Lymphoma",
        "Pancreatic Cancer",
        "Liver Cancer",
        "Colon Cancer",
        "Lung Cancer",
        "Bile Duct Cancer",
        "Chordoma of Sacrum",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "INT230-6",
          "type": "DRUG"
        },
        {
          "name": "anti-PD-1 antibody",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-CTLA-4 antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Intensity Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2017-02-09",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03058289"
    },
    {
      "nct_id": "NCT00003543",
      "title": "Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody A33",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "streptozocin",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "1998-06",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-27",
      "last_synced_at": "2026-06-25T12:10:14.769Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003543"
    }
  ]
}